Takeshi Mochizuki1, Katsunori Ikari2, Koichiro Yano2, Motoaki Sato3, Ken Okazaki4. 1. a Department of Rheumatology , Kamagaya General Hospital , Chiba , Japan. 2. b Institute of Rheumatology, Tokyo Women's Medical University , Tokyo , Japan. 3. c Department of Radiology , Kamagaya General Hospital , Chiba , Japan. 4. d Department of Orthopedic Surgery , Tokyo Women's Medical University , Tokyo , Japan.
Abstract
OBJECTIVE: To examine the deterioration of interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA) treated with abatacept over the long-term. METHODS: We examined 131 patients with RA who had been treated with abatacept for more than 1 year. All patients underwent high-resolution computed tomographic (HRCT) scanning of the chest before administration of abatacept, and we examined deterioration of ILD over a follow-up period after administration of abatacept was initiated. RESULTS: Eleven patients (8.4%) showed deterioration of ILD over a mean follow-up period of 47.8 months. The factors related to ILD deterioration were use of methotrexate (MTX) [odds ratio 12.75, 95% confidence interval (CI) 1.09-148.77], and change in Krebs von-den Lungen-6 (odds ratio 1.00, 95% CI 1.00-1.01), according to multivariate logistic regression analysis. CONCLUSION: MTX in patients with RA treated with abatacept was a risk factor for deterioration of ILD. Discontinuation of MTX should be considered one of treatment reduction to prevent the deterioration of ILD.
OBJECTIVE: To examine the deterioration of interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA) treated with abatacept over the long-term. METHODS: We examined 131 patients with RA who had been treated with abatacept for more than 1 year. All patients underwent high-resolution computed tomographic (HRCT) scanning of the chest before administration of abatacept, and we examined deterioration of ILD over a follow-up period after administration of abatacept was initiated. RESULTS: Eleven patients (8.4%) showed deterioration of ILD over a mean follow-up period of 47.8 months. The factors related to ILD deterioration were use of methotrexate (MTX) [odds ratio 12.75, 95% confidence interval (CI) 1.09-148.77], and change in Krebs von-den Lungen-6 (odds ratio 1.00, 95% CI 1.00-1.01), according to multivariate logistic regression analysis. CONCLUSION:MTX in patients with RA treated with abatacept was a risk factor for deterioration of ILD. Discontinuation of MTX should be considered one of treatment reduction to prevent the deterioration of ILD.
Authors: Esteban Cano-Jiménez; Tomás Vázquez Rodríguez; Irene Martín-Robles; Diego Castillo Villegas; Javier Juan García; Elena Bollo de Miguel; Alejandro Robles-Pérez; Marta Ferrer Galván; Cecilia Mouronte Roibas; Susana Herrera Lara; Guadalupe Bermudo; Marta García Moyano; Jose Antonio Rodríguez Portal; Jacobo Sellarés Torres; Javier Narváez; María Molina-Molina Journal: Sci Rep Date: 2021-04-28 Impact factor: 4.379